• Home
  • 1229P A multicenter phase II study of sotigalimab (CD40 agonist) in combination with neoadjuvant chemoradiation for resectable esophageal and gastroesophageal junction (GEJ) cancers.

1229P A multicenter phase II study of sotigalimab (CD40 agonist) in combination with neoadjuvant chemoradiation for resectable esophageal and gastroesophageal junction (GEJ) cancers.

Author List
A.H. Ko, M. Noel, J. Chao, D. Sohal, M. Crow, P.E. Oberstein, A. Scott, A. McRee, C. Rocha Lima, L. Fong, B. Keenan, E. Filbert, F.J. Hsu, V. Shankaran
Publication
Annals of Oncology
Publication ID (Profile URL)
https://researcherprofiles.org/profile/420600775
Publication Year
2022
Publication Title
A.H. Ko, M. Noel, J. Chao, D. Sohal, M. Crow, P.E. Oberstein, A. Scott, A. McRee, C. Rocha Lima, L. Fong, B. Keenan, E. Filbert, F.J. Hsu, V. Shankaran. 1229P A multicenter phase II study of sotigalimab (CD40 agonist) in combination with neoadjuvant chemoradiation for resectable esophageal and gastroesophageal junction (GEJ) cancers. Annals of Oncology. 2022 Sep 1; 33:s1111.